产品详情与公司简介
产品详情
| 中文名称： | Nutlin3 | 中文别名： | Nutlin3 |
|---|---|---|---|
| 英文名称： | Nutlin3 | CAS： | 548472-68-0 |
| 产品分类： | 小分子化合物 | 纯度： | ≥98% |
| 产品编号 | 品牌 | 纯度 | 规格 | 库存 | 价格 |
|---|---|---|---|---|---|
| IN4610 | 索莱宝 | ≥98% | 5mg | 有现货 | 870.00 元 |
| IN4610 | 索莱宝 | ≥98% | 1mg | 有现货 | 340.00 元 |
| IN4610 | 索莱宝 | ≥98% | 10mg | 有现货 | 1,290.00 元 |
| IN4610 | 索莱宝 | ≥98% | 25mg | 有现货 | 2,420.00 元 |
| IN4610 | 索莱宝 | ≥98% | 50mg | 有现货 | 3,870.00 元 |
| IN4610 | 索莱宝 | ≥98% | 100mg | 有现货 | 5,610.00 元 |
| 标准名称: | 4-[4,5-双(4-氯苯基)-2-(4-甲氧基-2-异丙氧基苯基)-4,5-二氢咪唑-1-羰基]哌嗪-2-酮 | 英文名称： | Nutlin-3 |
|---|---|---|---|
| CAS： | 548472-68-0 | 分子式： | C30H30Cl2N4O4 |
| 分子量： | 581.489605426788 | 颜色与性状： | 固体 |
| 密度： | 沸点： | ||
| 熔点： | 水溶性： |
| CAS | 548472-68-0 |
| 英文名称 | Nutlin3 |
| 分子式 | C30H30Cl2N4O4 |
| 分子量 | 581.49 |
| 规格 | 5mg ; 1mg ; 10mg ; 25mg ; 50mg ; 100mg |
| 溶解性 | Soluble in DMSO ≥5mg/mL |
| 纯度 | ≥98% |
| 级别 | Cell Culture |
| 外观(性状) | White to off-white Solid |
| 储存条件 | Powder:-20℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| 运输条件 | 冷藏运输 |
| MDL | MFCD07784509 |
| SMILES | CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl |
| InChIKey | BDUHCSBCVGXTJM-UHFFFAOYSA-N |
| InChI | InChI=1S/C30H30Cl2N4O4/c1-18(2)40-25-16-23(39-3)12-13-24(25)29-34-27(19-4-8-21(31)9-5-19)28(20-6-10-22(32)11-7-20)36(29)30(38)35-15-14-33-26(37)17-35/h4-13，16，18，27-28H，14-15，17H2，1-3H3，(H，33，37) |
| PubChem CID | 216345 |
| 靶点 | MDM-2 |
| 通路 | Apoptosis |
| 背景说明 | 是一种 MDM2 拮抗剂，抑制 MDM2-p53 相互作用 。 |
| 生物活性 | Nutlin-3 is a commercial available p53-MDM2 inhibitor， with Ki of 90 nM.[1-3] |
| 生物活性 | Nutlin-3 is a commercial available p53-MDM2 inhibitor， with Ki of 90 nM.[1-3] |
| IC50 | Ki: 90 nM (p53-MDM2)[1] |
| IC50 | Ki: 90 nM (p53-MDM2)[1] |
| In Vitro | Nutlin-3 is an inhibitor of the MDM2-p53 interaction. In particular， co-treatment of p53-positive HCT116 cells with 1 μM of Inauhzin and 2 μM of Nutlin-3 more significantly activated p53 as measured by its protein level as well as the level of its target p21， PUMA or cleaved PARP as indication of apoptosis[2]. Nutlin-3 is a small-molecule inhibitor that acts to inhibit MDM2 binding to p53 and subsequent p53-dependent DNA damage signaling. As a single agent， Nutlin-3 (2-10 μM) stabilizes p53 and p21WAF levels and is toxic to WTp53-22RV1 cells (IC50， 4.3 μM) but has minimal toxicity toward p53-deficient cells (IC50， >10 μM). Nutlin-3 induces p53 and p21WAF expression in a dose-dependent manner in 22RV1 cells. Short-term cell cycle assays show that， at a dose of 10 μM， Nutlin-3 increasea slightly the G1-phase fraction and decreasea S-phase fraction of all three cell lines[3]. |
| In Vitro | Nutlin-3 is an inhibitor of the MDM2-p53 interaction. In particular， co-treatment of p53-positive HCT116 cells with 1 μM of Inauhzin and 2 μM of Nutlin-3 more significantly activated p53 as measured by its protein level as well as the level of its target p21， PUMA or cleaved PARP as indication of apoptosis[2]. Nutlin-3 is a small-molecule inhibitor that acts to inhibit MDM2 binding to p53 and subsequent p53-dependent DNA damage signaling. As a single agent， Nutlin-3 (2-10 μM) stabilizes p53 and p21WAF levels and is toxic to WTp53-22RV1 cells (IC50， 4.3 μM) but has minimal toxicity toward p53-deficient cells (IC50， >10 μM). Nutlin-3 induces p53 and p21WAF expression in a dose-dependent manner in 22RV1 cells. Short-term cell cycle assays show that， at a dose of 10 μM， Nutlin-3 increasea slightly the G1-phase fraction and decreasea S-phase fraction of all three cell lines[3]. |
| In Vivo | Nutlin-3 can suppress the growth of xenograft tumors derived from human osteosarcoma or leukemia cells， the anti-tumor activity of Nutlin-3 even at the dose of 200 mg/kg per oral administration is marginal in an HCT116-derived xenograft tumor model[2]. Nutlin-3 may be a useful adjunct to improve the therapeutic ratio using precision radiotherapy targeted to hypoxic cells and warrants further study in vivo[3]. |
| In Vivo | Nutlin-3 can suppress the growth of xenograft tumors derived from human osteosarcoma or leukemia cells， the anti-tumor activity of Nutlin-3 even at the dose of 200 mg/kg per oral administration is marginal in an HCT116-derived xenograft tumor model[2]. Nutlin-3 may be a useful adjunct to improve the therapeutic ratio using precision radiotherapy targeted to hypoxic cells and warrants further study in vivo[3]. |
| 细胞实验 | Human non-small-cell lung carcinoma wild type p53-containing H460 and A549， human non-small-cell lung carcinoma p53-null H1299， and human colon cancer HCT116 (p53+/+ and p53-/-) cells are used. Cells (1.5×105) are plated into 6-well plates， and incubated at 37°C overnight. After treatment of Inauhzin and Nutlin 3 at the indicated concentrations for 48 h， cells are harvested， fixed in 70% ice-cold ethanol overnight at -20°C， resuspended in propidium iodide-solution (50 μg/mL PI， 0.1 mg/mL RNase A， 0.05% Tritin X-100 in PBS) for 40 min at 37°C， then analyzed for DNA content using a flow cytometer and proprietary software[2]. |
| 细胞实验 | Human non-small-cell lung carcinoma wild type p53-containing H460 and A549， human non-small-cell lung carcinoma p53-null H1299， and human colon cancer HCT116 (p53+/+ and p53-/-) cells are used. Cells (1.5×105) are plated into 6-well plates， and incubated at 37°C overnight. After treatment of Inauhzin and Nutlin 3 at the indicated concentrations for 48 h， cells are harvested， fixed in 70% ice-cold ethanol overnight at -20°C， resuspended in propidium iodide-solution (50 μg/mL PI， 0.1 mg/mL RNase A， 0.05% Tritin X-100 in PBS) for 40 min at 37°C， then analyzed for DNA content using a flow cytometer and proprietary software[2]. |
| 动物实验 | Mice[2] Five-week-old female SCID mice are used. Mice are subcutaneously inoculated with 3×106 HCT116p53+/+ cells in the right flank and tumor growth is monitored with calipers. After the mean tumor volume reaches 50-100 mm3， animals are administered Inauhzin intraperitoneally (IP)， Nutlin 3 orally， or vehicles (4% DMSO for Inauhzin， EtOH: Tween: 5% Glucose=5:5:90 for Nutlin 3). Tumor volume is measured every other day， and inhibition of tumor growth (T/C) is calculated on the last day of treatment. |
| 动物实验 | Mice[2] Five-week-old female SCID mice are used. Mice are subcutaneously inoculated with 3×106 HCT116p53+/+ cells in the right flank and tumor growth is monitored with calipers. After the mean tumor volume reaches 50-100 mm3， animals are administered Inauhzin intraperitoneally (IP)， Nutlin 3 orally， or vehicles (4% DMSO for Inauhzin， EtOH: Tween: 5% Glucose=5:5:90 for Nutlin 3). Tumor volume is measured every other day， and inhibition of tumor growth (T/C) is calculated on the last day of treatment. |
| 数据来源文献 | [1]. Yu Z， et al. Design， synthesis and biological evaluation of sulfamide and triazole benzodiazepines as novel p53-MDM2 inhibitors. Int J Mol Sci. 2014 Sep 5;15(9):15741-53. [2]. Zhang Y， et al. Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth.Cancer Biol Ther. Cancer Biol Ther. 2012 Aug;13(10):915-24. [3]. Supiot S， et al. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther. 2008 Apr;7(4):993-9. |
| 数据来源文献 | [1]. Yu Z， et al. Design， synthesis and biological evaluation of sulfamide and triazole benzodiazepines as novel p53-MDM2 inhibitors. Int J Mol Sci. 2014 Sep 5;15(9):15741-53. [2]. Zhang Y， et al. Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth.Cancer Biol Ther. Cancer Biol Ther. 2012 Aug;13(10):915-24. [3]. Supiot S， et al. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53. Mol Cancer Ther. 2008 Apr;7(4):993-9. |
| 单位 | 瓶 |
| 1mM-5mg | 8.5986mL |
| 1mM-1mg | 1.7197mL |
| 1mM-10mg | 17.1972mL |
| 5mM-1mg | 0.3439mL |
| 5mM-5mg | 1.7197mL |
| 5mM-10mg | 3.4394mL |
| 10mM-1mg | 0.172mL |
| 10mM-5mg | 0.8599mL |
| 10mM-10mg | 1.7197mL |
公司简介
公司拥有一批专业的研发人员，我们专注于生物产品的不断完善和创新。产品覆盖面广，品质可靠。先后开发了涵盖分子生物学、细胞生物学、免疫学、生物医学等领域的多种试剂及试剂盒。同时，索莱宝公司提供各种常规生化试剂，库存常备产品多达10000多种，可随时为广大科研工作者提供各类专业试剂。在质量方面，索莱宝谨记公司信念：质量高于一切。所有研发的产品都设有严谨的生产流程，科学的质量检测方法和成熟的质量检测程序，我们恪守对每一位用户的承诺：用专业的态度做专业的品牌。同时，公司组建了一支专业的技术服务队伍，能够为科研工作者提供专业的技术服务。每一位购买索莱宝产品的用户都能够得到专业的咨询和完善的售后服务。
索莱宝公司坚持与国际接轨，注重和国际先进企业的合作与交流，并提供产品代理、市场咨询等多项服务。公司将一如既往与世界更多知名品牌合作，不断为广大生物科研工作者提供更优质的产品和服务。公司理念：“为科研服务，为生命尽责”。一个人能够走多远，取决于与谁同行。索莱宝公司期待与各同行精诚合作。
索莱宝诚招生物试剂研发人员，期待与广大同行精诚合作，为广大科研工作者提供优质的产品，高效的物流以及专业的售后服务。索莱宝感谢所有朋友的支持与帮助，您的支持是我们前进的动力和保障。让我们携手同行，共同创造美好的明天。
| 企业认证： | 已认证 | 企业性质： | 生产研发 |
|---|---|---|---|
| 主营产品： | 重组人透明质酸酶 ； 乙醇中25-羟基维生素D3标准溶液 100μg/mL ； 乙醇中25-羟基维生素D2标准溶液 100μg/mL ； 尼妥珠单抗 ； (+)-冰片 ； | 供货范围： | 试剂 |
| 产品目录： | 119719 | 品牌： | 索莱宝 |
店内推荐
-
-
产品详情：中文名称:乙醇中25-羟基维生素D3标准溶液 100μg/mL 英文名称:25-Hydroxyvitamin D3 standard solution in ethanol CasNo:19356-17-3 更多信息请点击详情查看乙醇中25-羟基维生素D3标准溶液 100μg/mL 商品补充信息 纯度 品牌 规格 发货地 - 索莱宝 1ml 北京
免责声明 ：以上所展示的信息由企业自行提供，内容的真实性、准确性和合法性由发布企业负责，960化工网对此不承担任何保证责任。我们原则上建议您选择960化工网会员。
960化工网为您提供Nutlin3的专业供应商信息，包括公司名称，地址，手机，电话，以及该供应商的其他产品和相关产品,wap 版：Nutlin3